Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual vs Oral Estradiol with CPA on Coagulation in Transgender Women
NCT07145281Completed
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Nov 2022
- Primary completion
- Nov 2024
- Modality
- Hormone, Biologic
- Countries
- 1
01
Overview
Open-label trial of estradiol in gender dysphoria (GD) (2 arms), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoint: Change from Baseline in Plasma Free Protein S Antigen Concentration at 6 months. Started Nov 2022; status: completed.
02
Drugs
estradiol
03
Conditions
gender dysphoria (GD)
Beyond the preview
Go deeper on NCT07145281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07145281.